Brigitte C. Widemann

Jan 6, 2025 | nature.com | Brigitte C. Widemann

AbstractThe MEK inhibitor selumetinib induces objective responses and provides clinical benefit in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

Oct 27, 2023 | onlinelibrary.wiley.com | Subhashini Jagu |Elaine R. Mardis |Brigitte C. Widemann |Mary F. Wedekind

CONFLICT OF INTEREST STATEMENT The authors have no conflicts of interest to declare. REFERENCES 1, , , et al. The Childhood Cancer Data Initiative: using the power of data to learn from and improve outcomes for every child and young adult with pediatric cancer. J Clin Oncol. 2023; 41: 4045-4053. 10.1200/JCO.22.02208 2 National Cancer Institute. Childhood Cancer Data Initiative Hub. National Cancer Institute. Accessed July 12, 2023. https://ccdi.cancer.gov/home 3 National Cancer Institute.